Acne News and Research

Latest Acne News and Research

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.

29 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

AADA releases updated position statement on isotretinoin usage

The American Academy of Dermatology Association (AADA) recently updated its position statement on the use of isotretinoin. The position continues to state that patient safety is dermatologists' primary concern and that the AADA is committed to the safe and responsible use of isotretinoin, which is the most effective treatment for severe acne.

23 Nov 2010

Obagi Medical Products prices secondary offering

Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today announced the pricing of the secondary public offering of 2,690,244 shares of its common stock by the Stonington Capital Appreciation 1994 Fund, L.P. and the Zein and Samar Obagi Family Trust, at a public offering price of $10.25 per share.

20 Nov 2010

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

19 Nov 2010

Acne, acne medicine and mental health: Study

Acne drug Accutane (isotretinoin) has been plagued by serious controversies with some linking it to suicidal tendencies. Now the latest research finds that severe acne itself increases the risk for suicidal thoughts and actions, raising more questions about the role of the drug, if any, in suicide.

14 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.

12 Nov 2010

New Alma’s Soprano laser technology delivers painless procedure for hair removal

Alma Lasers, Ltd., a leader in laser, light, radiofrequency and ultrasound-based aesthetic devices, unveils the latest in next generation medical laser technology with the debut of its new Soprano(XLi) for laser hair removal and deep dermal heating.

12 Nov 2010

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

9 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

30 Oct 2010

State Watch: R.I. group experiments with payment reform; Ariz. dispute over abortion; Vt. and Feds to end monitoring of caregivers

The Providence (R.I.) Journal: "The Lifespan hospital group and Blue Cross have reached an agreement intended to gradually overturn the way hospital care is financed, with the goal of promoting health, rather than episodes of treatment. The agreement is the first to meet unique-in-the-nation rules from state Health Insurance Commissioner Christopher F. Koller, who has identified hospital costs as the main reason for increases in health-insurance premiums.

30 Oct 2010

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. The Phase III safety study is being conducted under a Special Protocol Assessment that was granted by the U.S. Food and Drug Administration (FDA).

29 Oct 2010

First Edition: October 27, 2010

Today's headlines note that the new health law has Democrats playing defense, while Republicans offer few new alternatives to the sweeping measure.

27 Oct 2010

Cipher reports net revenue of $1.1 million for 2010 third quarter

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and nine months ended September 30, 2010.

27 Oct 2010

Stress can literally show up on the face

According to an Australian stylist stress affects the health as well as appearance. Gregory Landsman, the author of Face and Fitness said that high stress level is immediately visible on a person’s face.

26 Oct 2010

Syneron launches VelaBABE device for women to reclaim pre-baby body

Syneron Medical Ltd., a leading medical aesthetic device innovator, is announcing their new VelaBABE promotion for women who want to reclaim their pre-baby body with help from VelaShape.

19 Oct 2010

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.

18 Oct 2010

Solta Medical announces acquisition of CLRS Technology

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has acquired privately-held CLRS Technology, a provider of personal care solutions based in Costa Mesa, California.

18 Oct 2010

Acne News and Research

Latest Acne News and Research

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

AADA releases updated position statement on isotretinoin usage

Obagi Medical Products prices secondary offering

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Acne, acne medicine and mental health: Study

NovaBay third quarter net loss increases to $1.6 million

New Alma’s Soprano laser technology delivers painless procedure for hair removal

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

State Watch: R.I. group experiments with payment reform; Ariz. dispute over abortion; Vt. and Feds to end monitoring of caregivers

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

First Edition: October 27, 2010

Cipher reports net revenue of $1.1 million for 2010 third quarter

Stress can literally show up on the face

Syneron launches VelaBABE device for women to reclaim pre-baby body

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

Solta Medical announces acquisition of CLRS Technology

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Acne News and Research

Latest Acne News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in